Literature DB >> 25433018

Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs.

E H Vogelzang1, M F Pouw2, M Nurmohamed1, E L Kneepkens1, T Rispens3, G J Wolbink2, C L M Krieckaert1.   

Abstract

Entities:  

Keywords:  DMARDs (biologic); Pharmacokinetics; Psoriatic Arthritis; Rheumatoid Arthritis

Mesh：

Substances：

Year:  2014        PMID： 25433018     DOI： 10.1136/annrheumdis-2014-206588

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  11 in total

Review 1.  Tumor necrosis factor inhibitors in psoriatic arthritis.

Authors:  Santhi Mantravadi; Alexis Ogdie; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2017-05-22       Impact factor: 5.045

Review 2.  Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.

Authors:  Joachim R Kalden; Hendrik Schulze-Koops
Journal:  Nat Rev Rheumatol       Date:  2017-11-21       Impact factor: 20.543

3.  Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.

Authors:  C I Busard; S P Menting; J S van Bezooijen; J M van den Reek; B A Hutten; E P Prens; E M de Jong; M B van Doorn; P I Spuls
Journal:  Trials       Date:  2017-02-02       Impact factor: 2.279

4.  Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab.

Authors:  Eline De Keyser; Celine I Busard; Sven Lanssens; Lieve Meuleman; Barbara A Hutten; Antonio Costanzo; Juul M van den Reek; Jeffrey Zweegers; Jo Lambert; Phyllis I Spuls
Journal:  Ther Drug Monit       Date:  2019-10       Impact factor: 3.681

5.  What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?

Authors:  Puja Mehta; Jessica J Manson
Journal:  Front Immunol       Date:  2020-04-07       Impact factor: 7.561

6.  Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis.

Authors:  Nils Bolstad; Hilde Berner Hammer; Johanna Elin Gehin; Silje Watterdal Syversen; David John Warren; Guro Løvik Goll; Joseph Sexton
Journal:  RMD Open       Date:  2021-12

7.  Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis.

Authors:  Borja Hernández-Breijo; Claudia M Brenis; Chamaida Plasencia-Rodríguez; Ana Martínez-Feito; Marta Novella-Navarro; Dora Pascual-Salcedo; Alejandro Balsa
Journal:  Front Med (Lausanne)       Date:  2021-06-29

8.  CD147 monoclonal antibody mediated by chitosan nanoparticles loaded with α-hederin enhances antineoplastic activity and cellular uptake in liver cancer cells.

Authors:  Rong Zhu; Chun-ge Zhang; Yang Liu; Zhi-qiang Yuan; Wei-liang Chen; Shu-di Yang; Ji-zhao Li; Wen-jing Zhu; Xiao-feng Zhou; Ben-gang You; Xue-nong Zhang
Journal:  Sci Rep       Date:  2015-12-07       Impact factor: 4.379

Review 9.  The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis.

Authors:  Martin Perry; Azhar Abdullah; Marina Frleta; Jonathan MacDonald; Andrew McGucken
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-02-07       Impact factor: 5.346

Review 10.  Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies.

Authors:  Tawfik Khoury; Yaron Ilan
Journal:  Front Immunol       Date:  2019-11-20       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.